Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 09 Mar 2017 Planned End Date changed from 1 Jun 2021 to 1 Mar 2021.
- 09 Mar 2017 Planned primary completion date changed from 1 Jun 2021 to 1 Mar 2021.
- 09 Mar 2017 Status changed from not yet recruiting to recruiting.